Last $0.10 USD
Change Today -0.0035 / -3.32%
Volume 81.2K
ISCO On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 3:29 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

international stem cell corp (ISCO) Snapshot

Open
$0.11
Previous Close
$0.11
Day High
$0.11
Day Low
$0.10
52 Week High
12/12/13 - $0.30
52 Week Low
07/9/14 - $0.06
Market Cap
21.8M
Average Volume 10 Days
269.7K
EPS TTM
$-0.07
Shares Outstanding
213.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTERNATIONAL STEM CELL CORP (ISCO)

international stem cell corp (ISCO) Related Bloomberg News

View More Bloomberg News

international stem cell corp (ISCO) Related Businessweek News

No Related Businessweek News Found

international stem cell corp (ISCO) Details

International Stem Cell Corporation, a biotechnology company, focuses on the development of therapeutic and biomedical products worldwide. Its products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cells. The company develops cell types, such as neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat congenital and acquired liver diseases; islet cells for the treatment of diabetes; and three-dimensional eye structures to treat degenerative retinal diseases and corneal blindness, as well as to accelerate corneal healing. It also offers cosmetic skin care products through professional channels and distributors, as well as through a branded Website; and human cell culture products for use in pharmaceutical, academic, and government research organizations. The company’s human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines to study breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. The company offers its human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California.

42 Employees
Last Reported Date: 03/21/14
Founded in 2001

international stem cell corp (ISCO) Top Compensated Officers

Co-Chairman and Chief Executive Officer
Total Annual Compensation: $258.5K
Executive Vice President of Business Developm...
Total Annual Compensation: $220.0K
Chief Scientific Officer and Director
Total Annual Compensation: $182.0K
Compensation as of Fiscal Year 2013.

international stem cell corp (ISCO) Key Developments

International Stem Cell Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

International Stem Cell Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced total revenue of $1,588,000 compared to $1,457,000 for the same period a year ago. Loss from operating activities was $2,243,000 compared to $2,190,000 for the same period a year ago. Loss before income taxes was $4,410,000 compared to $2,200,000 for the same period a year ago. Net loss was $4,410,000 compared to $2,200,000 for the same period a year ago. Net loss applicable to common stockholders was $4,410,000 compared to $2,200,000 for the same period a year ago. Net loss per common share, basic and diluted was $0.03 compared to $0.02 for the same period a year ago. Increase in loss is due to below-the-line expense related to the warrant exchange transaction. For the six months, the company announced total revenue of $3,237,000 compared to $2,742,000 for the same period a year ago. Loss from operating activities was $4,308,000 compared to $3,904,000 for the same period a year ago. Loss before income taxes was $5,845,000 compared to $3,913,000 for the same period a year ago. Net loss was $5,845,000 compared to $3,913,000 for the same period a year ago. Net loss applicable to common stockholders was $5,845,000 compared to $3,913,000 for the same period a year ago. Net loss per common share, basic and diluted was $0.04 compared to $0.04 for the same period a year ago.

International Stem Cell Corporation, Q2 2014 Earnings Call, Aug 12, 2014

International Stem Cell Corporation, Q2 2014 Earnings Call, Aug 12, 2014

International Stem Cell Corporation Launches Stroke Program with Tulane University

International Stem Cell Corporation announced that it has launched a new Stroke Program. Together with Tulane University, ISCO will study the impact of human parthenogenetic neural stem cells (hpNSC) transplantation in a pre-clinical rodent model of ischemic stroke as a first step toward the clinical development of a potential stroke treatment. The proof-of-concept study will be done in the laboratory of Dr. Jean-Pyo Lee, a well-known expert in the field of regenerative medicine. Although stroke is known to cause long-term neurological disability, there is evidence that transplantation of NSC may improve patient outcomes as an adjunctive therapeutic strategy. ISCO's new stroke program will use the same cellular product as the Parkinson's disease program. There is significant overlap in the safety datasets and manufacturing methods that would be required to file an IND for stroke, making it a logical follow-on indication. hpNSC generated from ISCO's propriety human parthenogenetic stem cells using a cGMP method based on the published protocol are already under development for the treatment of Parkinson's disease. The Company has a considerable amount of safety data on hpNSC from the previously discussed studies in the Parkinson's program that are designed to support the planned IND filing, including evidence from the primate studies that these cells can reduce brain inflammation. According to the National Stroke Association stroke is a leading cause of death In the United States, killing nearly 130,000 people each year, and a leading cause of serious, long-term adult disability. Approximately 795,000 strokes will occur each year, one occurring every 40 seconds, and taking a life approximately every four minutes. About 87% of strokes are ischemic. Approximately two million brain cells die every minute during stroke, increasing the risk of permanent brain damage, disability or death. The estimated direct and indirect cost of stroke in the United States in 2010 is $73.7 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISCO:US $0.10 USD -0.0035

ISCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bioheart Inc $0.03 USD -0.0008
BioTime Inc $2.92 USD -0.11
Cytori Therapeutics Inc $1.54 USD -0.10
ReNeuron Group PLC 3.50 GBp +0.025
StemCells Inc $1.56 USD +0.015
View Industry Companies
 

Industry Analysis

ISCO

Industry Average

Valuation ISCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTERNATIONAL STEM CELL CORP, please visit www.internationalstemcell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.